What it sells
Creating a New Class of Drugs to Address Incurable Autoimmune Diseases
Business model breakdown
Workflow: what inputs become what output?
Engineers exosomes to deliver signals to multiple cell types simultaneously; prototypes therapeutics and de-risks candidates in human cell assays.
Economics: what it saves and how it charges
UnverifiedPreclinical biotech; value from pipeline licensing or partnership (hypothesis).
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Winter 2021 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.